Anxiety / Nervousness Mega Study
Contents
Anxiety / Nervousness
Anxiety / Nervousness

Tags

Anxiety / Nervousness
Anxiety
Nervousness
Nervous

Abstract

This mega-study analyzes Anxiety / Nervousness (Emotions) using aggregated N-of-1 observational data from 998 participants who contributed 13,546 measurements . We identified 1,826 statistically significant predictor-outcome relationships involving Anxiety / Nervousness.

Anxiety / Nervousness primarily acts as an outcome, influenced by 1,566 different factors. Effect sizes are reported as percent change from baseline following above-average predictor exposure.

Our analysis employs within-subject comparisons to control for individual differences, temporal precedence analysis to assess causality direction, and the Predictor Impact Score (PIS) to quantify causal evidence. See the ranked results below to explore the full list of factors predicting Anxiety / Nervousness.

Keywords: Anxiety / Nervousness, Emotions, N-of-1 trials, real-world evidence, causal inference, Predictor Impact Score, observational study

Full Methodology: Framework for Real-World Evidence-Based Pharmacovigilance: Aggregated N-of-1 Trials for Quantifying Treatment Effects

High Confidence: With 998 participants, these findings have strong statistical power. Results are significant at p < 0.05.

Results

Our analysis identified 1,826 statistically significant relationships involving Anxiety / Nervousness. These represent factors that predict changes in Anxiety / Nervousness.

Click any relationship in the tables below to view the full study page with detailed charts, statistical analysis, temporal parameters, and methodology for that specific predictor-outcome pair.

Relationship Network

The network graph below visualizes the relationships between Anxiety / Nervousness and related variables. Nodes represent variables, and edges represent statistically significant relationships. Click any node or edge to explore that relationship.

Causal Flow Diagram

The Sankey diagram below illustrates the flow of influence between predictors, Anxiety / Nervousness, and outcomes. The width of each flow corresponds to the strength of the relationship. Click any flow to see the detailed study.

Causes of Anxiety / Nervousness

User reported causes of Anxiety / Nervousness based on their intuition.

Cause Agree
Stress 96%
Uncomfortable Social Situations 75%
Lack of Sleep 72%
Depression 69%
New Situations 66%
Lack of Exercise 66%
Past Life Experiences 65%
Low Self-Esteem 61%
Genetic 60%
Work Environment 52%
Financial Stress 52%
Perfectionism 51%
Low Energy 47%
Poor Diet 46%
Public Speaking/presenting 40%
Large Crowds 40%
Rough Childhood 39%
Irregular Schedule 37%
Unemployment 36%
Caffeine 35%
Change of Seasons 35%
Hormonal Changes 34%
Family History of Emotional Abuse 32%
Big Open Ended Work Projects 31%
Low Serotonin 31%
Parents 31%
Sickness 25%
Difficult Breakup 25%
Post-Traumatic Stress Disorder (PTSD) 24%
Poverty 23%
Chronic Illness 22%
Hangover (Alcohol) 21%
Being a College Student 20%
Parenting Stress 18%
Marriage 18%
Adrenal Fatigue 16%
Divorce 16%
Abusive Relationship 16%
Death of Parent 15%
Sick Parent 15%
Hypothyroidism 14%
GERD 14%
Chronic Fatigue Syndrome 14%
Financial Aid Payments 13%
Violence 13%
Ostracism 13%
Court Trials Regarding Property 13%
Death of a Pet 12%
Autoimmune Disease 12%
Sickness of Pet 12%
Pornography 10%
Serious Illness of Spouse 10%
Autoimmune 9%
Sick Child 9%
Mitral Valve Prolapse 8%
Past Marijuana Use 8%
Parenting With an Ex 8%
Global Warming 7%
Death of Sibling 6%
Caregiver for Family Member With Alzheimer's 5%
Homelessness 5%
Asperger's 5%
Post Partum Depression 5%
Benzodiazepine Withdrawal 5%
Marijuana Use (Current) 5%
Death of Spouse 3%
Death of Child 3%
Breast Implant 2%
Child Support 2%
Rheumatoid Arthritis 2%
Multiple Sclerosis 1%
Brain Aneurysm 1%

Conditions Resulting from Anxiety / Nervousness

User-reported conditions resulting from Anxiety / Nervousness based on their intuition.

Resulting Condition Agree
Dermatillomania (Compulsive Skin Picking) 91%
Binge Eating 78%
Bruxism (Teeth Grinding) 77%
Irritable Bowel Syndrome 72%
Mitral Valve Prolapse 71%
Insomnia 70%
Tobacco Addiction 68%
Irregular Heart Beat (Arrhythmia) 67%
Ulcerative Colitis 66%
Fatigue 63%
Stomach Pain 62%
TMJ Disorder 61%
Fibromyalgia 60%
Interstitial Cystitis 60%
Asperger's Syndrome 60%
Vulvodynia 58%
Chronic Fatigue Syndrome 57%
Constipation 57%
Low Libido 52%
Migraine 52%
Vulvar Vestibulitis 48%
Restless Legs Syndrome 39%
Anal Fissures 36%
Gluten Intolerance 32%
Lower Back Pain 24%
Scar 7%

Treatments

User-reported effectiveness in treating Anxiety / Nervousness

Treatment Major Improvement Moderate Improvement Much Worse No Effect Worse Responses
Exercise 22% 50% 2% 23% 4% 1297
Osteopathy 11% 34% 3% 43% 9% 35
Tai Chi 7% 37% 4% 47% 5% 170
Acupuncture 8% 30% 6% 49% 6% 283
Biofeedback 7% 40% 4% 44% 4% 122
Cognitive Behavioral Therapy 18% 47% 2% 28% 5% 698
Amitriptyline 4% 19% 24% 38% 15% 141
Lyrica 15% 16% 25% 32% 12% 81
Vicodin 9% 51% 7% 22% 11% 45
Yoga 18% 51% 1% 28% 2% 593
Imipramine 5% 23% 16% 33% 23% 43
Celebrex 4% 12% 20% 52% 12% 25
Psychotherapy 12% 45% 2% 35% 6% 554
Medical Marijuana 24% 28% 13% 21% 14% 174
Tramadol 20% 33% 17% 20% 10% 30
Chiropractic 6% 31% 4% 49% 10% 109
Magnesium 6% 27% 2% 63% 3% 439
Vitamin D 4% 21% 3% 70% 2% 518
Vitamin C 8% 31% 0% 62% 0% 13
Massage Therapy 10% 48% 2% 36% 4% 550
Meditation 14% 51% 1% 30% 4% 714
Adderall 18% 38% 5% 25% 15% 40
Clonazepam 25% 44% 6% 19% 7% 307
Isolation Tank/Sensory Deprivation 40% 20% 0% 40% 0% 5
EFT Emotional Freedom Therapy 10% 27% 3% 56% 4% 71
Rhodiola Rosea 7% 26% 2% 60% 5% 42
Melatonin 3% 29% 8% 49% 12% 156
Nortriptyline 5% 27% 21% 33% 14% 63
Hypnotherapy 9% 30% 4% 54% 2% 90
Deep Breathing 10% 50% 1% 35% 4% 1171
Diazepam 26% 39% 7% 19% 8% 218
Omega 3 3% 20% 3% 72% 3% 169
Calcium 1% 9% 3% 83% 4% 378
Gluten Free Diet 8% 15% 0% 73% 4% 26
Helminthic Therapy 33% 0% 0% 67% 0% 3
Homeopathy 5% 25% 5% 56% 9% 128
Mirtazapine 4% 30% 19% 26% 22% 27
Relaxation 9% 46% 1% 40% 4% 1124
Pantothenic Acid 1% 16% 0% 78% 5% 77
N-Acetylcysteine 0% 13% 0% 88% 0% 8
Aromatherapy 3% 39% 6% 47% 5% 236
Low Dose Naltrexone 14% 57% 14% 14% 0% 7
Benadryl 2% 33% 5% 50% 10% 216
Prayer 16% 37% 3% 39% 5% 556
B Vitamins 2% 22% 2% 71% 3% 676
Sodium Valproate 0% 9% 36% 36% 18% 11
Avoiding Caffeine 12% 36% 2% 45% 5% 706
Cymbalta 13% 28% 16% 26% 17% 127
Fluoxetine 12% 31% 16% 31% 10% 255
Tryptophan 3% 35% 6% 50% 6% 80
Wellbutrin 7% 26% 13% 41% 14% 323
Sertraline (Zoloft) 12% 31% 10% 36% 11% 328
Paroxetine (Paxil) 12% 25% 21% 29% 14% 259
Venlafaxine (Effexor) 13% 30% 19% 26% 13% 247
Spending Time With Animals 19% 51% 1% 27% 2% 874
Alprazolam (Xanax) 29% 46% 6% 16% 3% 417
Spending Time Outdoors 13% 56% 0% 28% 2% 371
Lorazepam (Ativan) 26% 40% 5% 24% 6% 304
Inspiring Music 13% 52% 0% 32% 3% 464
Running/Jogging 19% 52% 0% 26% 2% 84
Sun Exposure 9% 57% 2% 30% 2% 355
Acceptance and Commitment Therapy 11% 53% 1% 32% 3% 75
Interpersonal Therapy 14% 46% 3% 33% 4% 137
Take Action on Root Cause if Within Power 36% 43% 0% 14% 7% 14
Exposure Therapy 16% 48% 7% 22% 7% 114
Luvox 75% 25% 0% 0% 0% 4
Dialectical Behavior Therapy 17% 42% 6% 23% 12% 52
Eye Movement Desensitization and Reprocessing (EMDR) 20% 26% 4% 41% 8% 99
Ashwagandha 13% 38% 0% 50% 0% 16
Alcohol Intoxication Avoidance 30% 30% 0% 20% 20% 10
Nuvoxil 50% 50% 0% 0% 0% 2
Propranalol 15% 39% 5% 33% 9% 103
Kratom (Mitragyna Speciosa) 100% 0% 0% 0% 0% 1
Transcranial Magnetic Stimulation 100% 0% 0% 0% 0% 1
Cytomel 18% 23% 5% 55% 0% 22
Vilazodone 0% 100% 0% 0% 0% 1
Phenibut 13% 25% 0% 63% 0% 8
Compounded SRT3 13% 50% 13% 25% 0% 8
Chill Pill Herb Blend 0% 50% 0% 50% 0% 4
Bromazepam 0% 50% 0% 50% 0% 4
Toprol (Metaprolol) 4% 54% 8% 33% 0% 24
Nofap 0% 50% 0% 50% 0% 2
NeuroPsychoImmunologie 50% 0% 0% 0% 50% 2
Bio-Identical Hormones 13% 36% 5% 41% 5% 56
Zopiclone 0% 67% 0% 0% 33% 3
Nightshade Avoidance 20% 10% 0% 60% 10% 10
Sleep Therapy 0% 33% 0% 33% 33% 3
Synthroid--Brand Rx 6% 29% 0% 59% 6% 17
Skullcap (Scutellaria Lateriflora) 7% 20% 0% 73% 0% 15
Ampligen 0% 0% 100% 0% 0% 1
Positive Thinking 7% 41% 3% 42% 7% 573
Antioxidant Therapy 0% 25% 0% 67% 8% 12
Seredyn 0% 38% 13% 38% 13% 8
L-Theanine 5% 34% 5% 56% 0% 62
Candida Yeast Diet 0% 29% 14% 43% 14% 7
12 Step Program 24% 21% 12% 29% 14% 42
Gabapetin 5% 26% 5% 53% 11% 19
Levothyroxine 9% 31% 5% 51% 5% 81
Olanzapine 0% 14% 14% 57% 14% 7
Intermittent Fasting 6% 19% 0% 50% 25% 16
MDMA 16% 40% 14% 12% 19% 43
Bacopa Aka Holy Basil 0% 9% 9% 73% 9% 11
Lamictal 15% 31% 12% 32% 9% 65
Chlorazepate (Tranxene) 8% 31% 23% 23% 15% 13
Kavanace 0% 36% 27% 27% 9% 11
Duloxetine 15% 26% 18% 35% 6% 34
Desipramine 10% 34% 17% 24% 14% 29
Escitalopram (Lexapro) 17% 32% 12% 27% 11% 254
Drinking Water 6% 27% 4% 59% 4% 128
Masturbation 5% 40% 3% 41% 11% 505
Stoicism 19% 13% 31% 25% 13% 16
Compounded Progesterone 2% 36% 11% 43% 7% 44
Passionflower 3% 32% 5% 51% 9% 91
Bach Flower Essence 4% 14% 4% 78% 0% 77
5-HTP 8% 27% 5% 49% 11% 183
Naprosyn SR 0% 22% 11% 52% 15% 27
Buspirone 13% 22% 10% 41% 14% 91
Gaba 4% 28% 8% 50% 10% 101
Chamomile 1% 28% 3% 64% 4% 424
Selenium 2% 9% 5% 82% 3% 65
Savella/milnacipran 13% 6% 50% 25% 6% 16
Citalopram (Celexa, Cipramil) 8% 36% 12% 34% 10% 278
Kava 5% 23% 4% 54% 14% 166
Avoiding Meat 7% 18% 5% 64% 7% 262
Pristiq (Desvenlafaxine) 8% 26% 25% 30% 11% 53
Quetiapine/Seroquel 16% 26% 28% 20% 10% 92
Valerian 3% 23% 5% 60% 8% 357
Risperidone/Risperdol 11% 11% 41% 19% 19% 27
Saint John's Wort 1% 18% 5% 67% 8% 204
Abilify (Aripiprazole) 0% 21% 28% 30% 21% 43
Exhausting Myself by Staying Awake 0% 16% 33% 16% 35% 49

Treatments Causing Anxiety / Nervousness

User-reported treatments that exhibited the side effect of Anxiety / Nervousness

Treatment Percent of Reports
Hydrocodone 17%
Neurontin 31%
Lyrica 33%
Pregabalin 33%
Corticosteroids 33%
Meditation 27%
Gabapentin (Neurontin) 31%
Pregabalin (Lyrica) 33%
Botox 13%
Hydrocortisone 24%
Mesalamine 15%
Armour 21%
Wellbutrin 43%
Venlafaxine (Effexor) 55%
Claritin 22%
Loratadine 22%
Aripiprazole 47%
Bupropion (Wellbutrin) 43%
Caffeine 42%
Zonegran 40%
Sumatriptan 20%

Predictors of Anxiety / Nervousness

The table below ranks predictors by their impact on Anxiety / Nervousness. Each row shows the percent change in Anxiety / Nervousness following above-average predictor exposure. Click any row to see the full analysis.

PUZZLED_ROBOT
Don't see what you're looking for?

Less than 1% of patients are able to participate in clinical trials! :(

Take 30 seconds to make it possible for all patients to easily participate in trials for the most promising treatments!

Predictors
of
Below is the change in after each predictor is higher than average.
Sort by % Change
Sort by Evidence
Sort by Participants
Predictor
% Change from Baseline
*
Change from average after above-average predictor exposure.
Note: Results are based on aggregated observational data. Confidence increases with more participants. Click any row for full study details.

Summary Statistics

Anxiety / Nervousness Info

Property Value
Variable Name Anxiety
Aggregation Method MEAN
Analysis Performed At 2022-10-07
Duration of Action 24 hours
Kurtosis 2.033986759222
Maximum Allowed Value 5 out of 5
Mean 3.0756713266762 out of 5
Median 3.0701780313837 out of 5
Minimum Allowed Value 1 out of 5
Number of Aggregate Predictors 1566
Number of Aggregate Outcomes 260
Number of Measurements 13546
Number of Measurements (including those generated by tagged, joined, or child variables) 13546
Public true
Onset Delay 0 seconds
Standard Deviation 0.31892876527387
Unit 1 to 5 Rating
User Variables 998
UPC 0
Variable Category Emotions
Variable ID 5903391
Variance 0.32180906187003

Introduction

Background

Anxiety / Nervousness (Emotions) is primarily a health outcome that may be influenced by various factors. Understanding the predictors and outcomes associated with Anxiety / Nervousness has important implications for personalized health optimization, clinical decision-making, and public health interventions. Traditional randomized controlled trials (RCTs), while the gold standard for causal inference, are often impractical for studying the full range of factors that may influence emotions.

Research Questions

This mega-study addresses the following research questions:

  1. What factors most strongly predict changes in Anxiety / Nervousness?
  2. Which predictors are modifiable vs. non-modifiable?
  3. What is the magnitude of predictor effects (percent change from baseline)?
  4. How confident can we be in these relationships?

Study Overview

We employ an aggregated N-of-1 observational study design, combining data from multiple individual longitudinal natural experiments. This approach leverages within-subject comparisons to control for stable individual differences while aggregating across participants to identify population-level patterns.

Discussion

Interpretation of Findings

The ranked tables in the Results section provide a comprehensive list of predictors, ordered by their effect size on Anxiety / Nervousness. Rather than focusing on any single relationship, the value lies in the full spectrum of factors identified and their relative effect sizes.

Context and Prior Research

These findings should be interpreted in the context of existing literature on Anxiety / Nervousness. While our observational design cannot establish causality with the certainty of randomized trials, the large sample size, within-subject design, and temporal precedence analysis provide converging evidence for the relationships identified.

Practical Implications

Individuals seeking to optimize their Anxiety / Nervousness may consider the predictors identified in this analysis, particularly those that are directly modifiable (e.g., behaviors, treatments, environmental factors). However, individual responses may vary, and these population-level findings should not replace personalized medical advice.

Future Directions

Future research should examine:

  • Subgroup analyses to identify individual differences in response
  • Potential confounders and mediators of the observed relationships
  • Optimal dosing and timing for modifiable predictors
  • Confirmation of key findings through prospective or randomized designs

Conclusion

The ranked tables above provide the complete list of factors predicting Anxiety / Nervousness, ordered by effect size.

These findings may inform evidence-based strategies for optimizing Anxiety / Nervousness. Individual responses may vary; consult healthcare providers for personalized guidance.

Help End Unnecessary Suffering

Current clinical trials are 82x more expensive than necessary and take 17 years to bring treatments to market. Pragmatic trials integrated into standard healthcare could reduce costs from $41,000 to $500 per participant and compress timelines to just 2 years. Learn how redirecting just 1% of global military spending could accelerate cures for the 2 billion people suffering from treatable diseases.

Methods

Study Design

Our analysis of Anxiety / Nervousness is based on aggregated data from 998 separate N-of-1 observational natural experiments. Unlike traditional clinical trials, our approach captures relationships in everyday life conditions, providing insights into how factors actually affect people outside controlled laboratory settings. Each participant serves as their own control, reducing between-subject confounding.

Baseline & Outcome Measurement

For each participant \(i\), we compute the mean predictor value and partition measurements into baseline (below-average exposure) and follow-up (above-average exposure) periods:

$$\text{Baseline}_i = \{(p, o) : p < \bar{p}_i\} \quad \text{Follow-up}_i = \{(p, o) : p \geq \bar{p}_i\}$$

The primary effect size is expressed as percent change from baseline:

$$\Delta\% = \frac{\mu_{\text{follow-up}} - \mu_{\text{baseline}}}{\mu_{\text{baseline}}} \times 100$$

This metric is interpretable ("15% reduction in symptoms"), scale-invariant, and consistent with FDA efficacy assessments.

Temporal Analysis & Causality Direction

Our analysis accounts for two critical temporal parameters:

  • Onset Delay (\(\delta\)): Time lag between predictor exposure and observable outcome change (0-100 days)
  • Duration of Action (\(\tau\)): Time window over which predictor influence persists (10 min - 90 days)

We compute both forward correlations (predictor → outcome) and reverse correlations (outcome → predictor) to calculate the temporality factor:

$$\phi_{\text{temporal}} = \frac{|r_{\text{forward}}|}{|r_{\text{forward}}| + |r_{\text{reverse}}|}$$

A temporality factor approaching 1.0 indicates the predictor reliably precedes the outcome, supporting a causal interpretation. Values near 0.5 suggest ambiguous temporal direction, while values approaching 0 suggest reverse causation.

Temporal Parameter Optimization

Different predictor-outcome pairs have different optimal temporal alignments. We employ hyperparameter optimization to find the onset delay and duration that maximize correlation strength:

$$(\delta^*, \tau^*) = \underset{\delta, \tau}{\text{argmax}} \; |r(\delta, \tau)|$$

The search begins with category-appropriate defaults (e.g., 30-minute onset for treatments) and explores physiologically plausible ranges. To prevent overfitting, we restrict searches to biologically plausible ranges and require minimum sample sizes.

Statistical Methods

We employ multiple statistical techniques:

  • Pearson Correlation Coefficient:
    $$r = \frac{\sum_{j=1}^{n}(p_j - \bar{p})(o_j - \bar{o})}{\sqrt{\sum_{j=1}^{n}(p_j - \bar{p})^2} \cdot \sqrt{\sum_{j=1}^{n}(o_j - \bar{o})^2}}$$
  • Z-Score Normalization: Effect magnitude relative to baseline variability:
    $$z = \frac{|\Delta\%|}{\text{RSD}_{\text{baseline}}}$$
    where \(z > 2\) indicates \(p < 0.05\) (statistically significant)
  • Two-Tailed T-Tests: Statistical significance assessed at \(\alpha = 0.05\)
  • 95% Confidence Intervals: \(\text{CI}_{95\%} = \bar{r} \pm 1.96 \cdot \text{SE}_{\bar{r}}\)

Effect Size Classification

Correlation strength is classified based on the absolute coefficient value:

Classification Correlation Range
Very Strong\(|r| \geq 0.8\)
Strong\(0.6 \leq |r| < 0.8\)
Moderate\(0.4 \leq |r| < 0.6\)
Weak\(0.2 \leq |r| < 0.4\)
Very Weak\(|r| < 0.2\)

Data Quality Requirements

To ensure reliable results, we enforce minimum thresholds:

  • ≥ 5 distinct value changes in both predictor and outcome variables
  • ≥ 30 overlapping measurement pairs (per Central Limit Theorem)
  • ≥ 10% of data in both baseline and follow-up periods
  • Non-zero variance in both predictor and outcome

Our filling strategy is deliberately conservative: zero-filling for treatments assumes non-adherence when no measurement exists, biasing toward null findings rather than false positives.

Predictor Impact Score (PIS)

We calculate a composite Predictor Impact Score that quantifies how much a predictor impacts an outcome:

$$\text{PIS} = |r| \cdot S \cdot \phi_z \cdot \phi_{\text{temporal}} \cdot f_{\text{interest}}$$

Where:

  • \(|r|\) = absolute correlation coefficient (strength)
  • \(S = 1 - p\) = statistical significance
  • \(\phi_z = \frac{|z|}{|z| + 2}\) = normalized z-score factor (effect magnitude)
  • \(\phi_{\text{temporal}}\) = temporality factor (forward vs. reverse causation)
  • \(f_{\text{interest}}\) = interest factor (penalizes spurious variable pairs)

Higher PIS values indicate predictors with greater, more reliable impact on the outcome.

Bradford Hill Criteria for Causality

While correlation does not prove causation, our PIS operationalizes six of the nine Bradford Hill criteria:

Criterion How Addressed Metric
StrengthEffect size magnitude\(|r|\), \(\Delta\%\)
ConsistencyCross-participant replication\(N\), \(n\), SE, CI
TemporalityForward vs. reverse correlation\(\phi_{\text{temporal}}\)
Biological GradientDose-response analysis\(\phi_{\text{gradient}}\)
SpecificityCategory appropriateness\(f_{\text{interest}}\)
PlausibilityCommunity votingUp/down votes

Confidence Levels

Each relationship is assigned a confidence level based on multiple factors:

  • High Confidence: \(p < 0.01\), or \(N > 100\) participants, or \(n > 500\) pairs
  • Medium Confidence: \(p < 0.05\), or \(N > 10\) participants, or \(n > 100\) pairs
  • Low Confidence: Meets minimum thresholds but requires more data

Limitations

Key limitations of this observational framework:

  • Cannot prove causation: Unmeasured confounders may influence results
  • Self-selection bias: Health trackers may differ from general population
  • Measurement error: Self-reported data may contain recall bias
  • Confounding by indication: Sicker patients may take more treatments

These findings represent population-level trends and should not replace personalized medical advice. Within-subject comparison and temporal precedence analysis partially mitigate these limitations.

Population Analysis

With 998 participants contributing data, our analysis benefits from the Law of Large Numbers: as sample size increases, random noise diminishes and true relationships become more apparent. Population-level estimates are computed as:

$$\bar{r} = \frac{1}{N} \sum_{i=1}^{N} r_i \quad \text{with} \quad \text{SE}_{\bar{r}} = \frac{\sigma_r}{\sqrt{N}}$$

Principal Investigator

Program & Methods

Mike P. Sinn

Designed and implemented data collection, aggregation, causal inference pipeline, and automated study generation framework. Developed the Predictor Impact Score methodology operationalizing Bradford Hill criteria for ranking causal relationships in observational data. When he tells people this at parties, they usually say they have to go check on their car.

Individual study outputs are automated, reproducible, and open to external audit. (Which I would seriously recommend.)

Cite This Study

APA Format
Sinn, M. P. (2026). Anxiety / Nervousness Mega-Study: Systematic Review of Predictive Factors [Data set; N=998]. The Decentralized FDA. http://studies.dfda.earth/variables/Anxiety
BibTeX
@misc{sinn_5903391_2026,
  author = {Sinn, Mike P.},
  title = {Anxiety / Nervousness Mega-Study: Systematic Review of Predictive Factors},
  year = {2026},
  publisher = {The Decentralized FDA},
  url = {http://studies.dfda.earth/variables/Anxiety},
  note = {Accessed: January 10, 2026},
  howpublished = {N=998 participants}
}
Chicago/Turabian
Sinn, Mike P. "Anxiety / Nervousness Mega-Study: Systematic Review of Predictive Factors." Data set, N=998. The Decentralized FDA. Accessed January 10, 2026. http://studies.dfda.earth/variables/Anxiety.
Harvard
Sinn, M.P., 2026. Anxiety / Nervousness Mega-Study: Systematic Review of Predictive Factors. [Aggregated N-of-1 Study, N=998] The Decentralized FDA. Available at: http://studies.dfda.earth/variables/Anxiety [Accessed January 10, 2026].

Study Type: Aggregated N-of-1 Observational Mega-Study
Evidence Level: Level II (Real-World Evidence)
Methodology: Bradford Hill Criteria with Predictor Impact Score (PIS)

References

This framework was originally developed in 2013 based on the Bradford Hill criteria. Subsequent literature has independently validated similar approaches to causal inference from observational data:

  1. Hill, A.B. (1965). The environment and disease: association or causation? Proceedings of the Royal Society of Medicine, 58(5), 295-300. [Bradford Hill criteria]
  2. Lillie, E.O., et al. (2011). The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine, 8(2), 161-173. [N-of-1 methodology]
  3. Pearl, J. (2009). Causality: Models, Reasoning, and Inference . Cambridge University Press. [Causal inference]
  4. Hernán, M.A., & Robins, J.M. (2020). Causal Inference: What If . Chapman & Hall/CRC. [Free textbook]
  5. FDA (2018). Framework for FDA's Real-World Evidence Program . U.S. Food and Drug Administration. [Regulatory context]
  6. Duan, N., et al. (2013). Single-patient (n-of-1) trials: a pragmatic clinical decision methodology . Journal of Clinical Epidemiology, 66(8), S21-S28.
  7. Platt, R., et al. (2018). The FDA Sentinel Initiative—an evolving national resource . New England Journal of Medicine, 379(22), 2091-2093.

This information is for research and educational purposes only, not medical advice. Consult a healthcare provider before making health decisions. Terms of Service